Phosphodiesterase 11A1 (PDE11A1)

Phosphodiesterase 11A1 (PDE11A1) is a splice variant of the PDE11A enzyme, a member of the phosphodiesterase family that hydrolyzes the secondary messengers cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) [1, 4]. As a dual-specificity enzyme, PDE11A1 regulates the intracellular levels of both cyclic nucleotides, thereby modulating signaling pathways critical for cellular homeostasis and endocrine regulation [1, 7]. This specific isoform is primarily expressed in the prostate, testis, and skeletal muscle, distinguishing it from other variants like PDE11A4 which is found in the brain [4, 5]. Mutations in the PDE11A gene are clinically significant as they are linked to the development of adrenocortical tumors and Cushing syndrome, where impaired PDE activity results in elevated cAMP levels [4, 8]. Furthermore, PDE11A1 is involved in physiological processes such as spermatogenesis and has been studied as a potential biomarker in various cancers [4, 7]. From a pharmacological perspective, PDE11A is a known off-target of the drug tadalafil, which may lead to side effects like myalgia due to its expression in skeletal muscle [10]. Research continues to explore the potential of targeting PDE11A for treating endocrine disorders and certain types of cancer [1, 10].

Other names

PDE11APhosphodiesterase 11AcAMP and cGMP-dependent phosphodiesterase 11A

Inhibition of the catalytic activity of the enzyme, preventing the hydrolysis of cyclic nucleotides (cAMP and cGMP), thereby increasing their intracellular concentrations and downstream signaling.